AstraZeneca Annual Report and Form 20-F Information 2008

Options to purchase securities from registrant or subsidiaries

(a) At 29 January 2009, options outstanding to subscribe for Ordinary Shares of $0.25 of the Company were:

Number of shares	Subscription price	Normal expiry date
55,640,140	1882p – 3487p	2009 – 2018

The weighted average subscription price of options outstanding at 29 January 2009 was 2519p. All options were granted under Company employee share schemes.

(b) Included in paragraph (a) are options granted to Directors and Officers of AstraZeneca as follows:

Number of shares	Subscription price	Normal expiry date
2,428,727	1882p – 3487p	2009 – 2018

(c) Included in paragraph (b) are options granted to individually named Directors. Details of these option holdings at 31 December 2008 are shown in the Directors’ Remuneration Report.

During the period 1 January 2009 to 29 January 2009, no Director exercised any options.